$32.00
Manufacturer: France
Treatment of physical and mental asthenia, accompanied by apathy and decreased activity. This medicinal product does not preclude the prescription of antidepressants in case of confirmation of the patient’s depressive episode.
Description
Enerion Storage
active substance: sulbutiamine;
1 tablet contains 200 mg of salbutiamine;
Enerion excipients: anhydrous glucose, lactose monohydrate, magnesium stearate, corn starch, pregelatinized starch, talc;
film coating: white wax, carmellose sodium, ethylcellulose, glycerol monooleate, polysorbate 80, povidone, colloidal anhydrous silica, sodium bicarbonate, sucrose, Yellow West FCF (E 110), talc, titanium dioxide.
Enerion Dosage form
Coated tablets.
Main physical and chemical properties: tablet, coated with orange sugar, biconvex shape.
Pharmacotherapeutic group
Vitamins. Vitamin B1 preparations, including in combination with vitamins B6 and B12. Simple preparations of vitamin B1. Salbutiamine. ATX code A11D A02.
Pharmacological properties
Pharmacodynamics.
Salbutiamine is an original molecule synthesized by modifications of thiamine. Due to these modifications, salbutiamine is able to penetrate the blood-brain barrier and accumulate in the structures of the brain, which causes such effects of the drug as:
improving coordination of movements;
increase resistance to muscle fatigue;
improving the resistance of the cerebral cortex to chronic hypoxia (oxygen starvation);
improving concentration and the ability to remember.
The effectiveness of Enerion® has been proven in many clinical placebo-controlled and comparative studies involving patients with functional asthenia of various etiologies, namely:
post-infectious asthenia, which occurs after acute viral and infectious diseases of the respiratory tract (bronchitis, tonsillitis, influenza), bacterial infections (Salmonella, Yersinia), tuberculosis, malaria, typhoid fever, infectious hepatitis;
asthenia, which occurs against the background of somatic diseases;
asthenia caused by depression;
asthenia in elderly patients: clinical studies have proven the effectiveness of Enerion® in mental disorders (memory, attention, alertness and thinking) and difficulties in social adaptation (fatigue, communication disorders, personality, behavior and sleep);
asthenia in students (physical and mental fatigue);
asthenia in athletes.
Pharmacokinetics.
Salbutiamine is rapidly absorbed, the maximum concentration in blood plasma is reached in 1-2 hours after ingestion.
The half-life is about 5 hours. Salbutiamine is excreted in the urine.
Indication
Treatment of physical and mental asthenia, accompanied by apathy and decreased activity.
This drug does not preclude the need for antidepressants in case of confirmation of a depressive episode in a patient.
Contraindication
Hypersensitivity to the active substance or to any of the excipients.
Interaction with other medicinal products and other forms of interaction
No special studies on the interaction of salbutiamine with other drugs have been performed.
Simultaneous application that requires attention
Diuretics: Increased urinary thiamine excretion (a metabolite of salbutiamine).
Muscle relaxants: when co-administered with thiamine (a metabolite of salbutiamine), the effect of these drugs may increase.
Recent Reviews